GGrantIndex
Sort

39,280 grants matching leukemia

Assessment of DCAF15 role in Acute Myeloid Leukemia

$483,760
Luca Busino · University Of Pennsylvania · R01 · FY2025 · CA

Targeting crotonyl-lysine chromatin readers to disrupt pathogenic gene expression in leukemia

$483,750
Michael A Erb · Scripps Research Institute, The · DP5 · FY2018 · OD

Targeting crotonyl-lysine chromatin readers to disrupt pathogenic gene expression in leukemia

$483,750
Michael A Erb · Scripps Research Institute, The · DP5 · FY2019 · OD

Targeting crotonyl-lysine chromatin readers to disrupt pathogenic gene expression in leukemia

$483,750
Michael A Erb · Scripps Research Institute, The · DP5 · FY2022 · OD

Targeting crotonyl-lysine chromatin readers to disrupt pathogenic gene expression in leukemia

$483,750
Michael A Erb · Scripps Research Institute, The · DP5 · FY2020 · OD

Targeting crotonyl-lysine chromatin readers to disrupt pathogenic gene expression in leukemia

$483,750
Michael A Erb · Scripps Research Institute, The · DP5 · FY2021 · OD

Project 2: Combined CAR-T cell therapy

$483,710
Gianpietro Dotti · Univ Of North Carolina Chapel Hill · P50 · FY2023 · CA

Implications of PARP1 in myelodysplastic syndromes and targeted therapy

$483,623
Dang Hai Nguyen · University Of Minnesota · R01 · FY2023 · HL

Amotosalen PCT of Leukapheresis Units for GvHD Therapy

$483,547
John Eugene Hearst · Transfusion And Transplantation Tech · R42 · FY2008 · HL

Myeloid Tumor Suppressor Gene Discovery from Chromosome Band 7q22

$483,413
Kevin M Shannon · University Of Chicago · P01 · FY2010 · CA

HMGA Chromatin Remodeling Proteins in Tumor Progression in Myeloproliferative Neoplasms (MPN)

$483,395
Linda M S Resar · Johns Hopkins University · R01 · FY2019 · HL

ALDH Activation to treat Fanconi Anemia

$483,345
Kenneth I. Weinberg · Stanford University · R01 · FY2020 · HL

Longitudinal Tumor Monitoring with Nanodevices

$483,318
Andrew Kummel · University Of California, San Diego · U54 · FY2008 · CA

Targeting altered phosphatase-dependent signaling to overcome the inefficacy of targeted therapy in myeloproliferative neoplasms

$483,261
Gary W Reuther · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2022 · HL

Dissecting the Functional Role of PAX5 Mutations in B-cell Acute Lymphoblastic Leukemia

$483,110
Zhaohui Gu · Beckman Research Institute/City Of Hope · R01 · FY2025 · CA

INNATE IMMUNE THERAPIES IN B CELL MALIGNANCIES

$483,061
John C Byrd · Ohio State University · P01 · FY2011 · CA

Development Of P2Y Receptor Ligands

$483,051
Kenneth Alan Jacobson · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2016 · DK

Integrating Epidemiologic and Genomic Data to Elucidate the Genetic Overlap Between Congenital Anomalies and Pediatric Cancer

$483,022
Chad Daniel Huff · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA

Meis1 Negatively Regulates Blood Flow in Hindlimb Ischemia

$483,000
Jia-Qiang He · Virginia Polytechnic Inst And St Univ · R15 · FY2018 · HL

Competing Supplement for CLL Research Consortium

$482,989
University Of California San Diego · P01 · FY2003 · CA

Novel Approaches to GHVD Prevention

$482,982
Joseph H Antin · Dana-Farber Cancer Inst · P01 · FY2007 · HL

Control Of G Protein Signaling: Role Of The RGSs

$482,966
John H Kehrl · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI

Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-operative Treatment Trials

$482,956
Nola M. Hylton · University Of California, San Francisco · R01 · FY2008 · CA

Genetic analysis of mouse chromosome 11

$482,909
Monica Jean Justice · Baylor College Of Medicine · R01 · FY2010 · CA

NCTN Deep South Research Consortium

$482,879
Charles A. Leath · University Of Alabama At Birmingham · UG1 · FY2020 · CA